Vaxcyte annual net debt
2019
2020
2021
2022
2023
2024
2025
Vaxcyte Net Debt Growth & History (PCVX)
Vaxcyte's net debt was −$56.4M for fiscal 2025.
View full Vaxcyte company overviewVaxcyte annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$56.4M | $260.4M | — |
| 2024 | 2024-12-31 | −$316.8M | $51.5M | — |
| 2023 | 2023-12-31 | −$368.2M | $448.5M | — |
| 2022 | 2022-12-31 | −$816.7M | −$764.5M | — |
| 2021 | 2021-12-31 | −$52.2M | $334.0M | — |
| 2020 | 2020-12-31 | −$386.2M | −$327.4M | — |
| 2019 | 2019-12-31 | −$58.8M | — | — |
Vaxcyte quarterly net debt
Q4.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$67.7M | $153.2M | — |
| Q1 2026 | 2026-03-31 | −$144.5M | $115.2M | — |
| Q4 2025 | 2025-12-31 | −$56.4M | $260.4M | — |
| Q3 2025 | 2025-09-30 | −$196.6M | $825.6M | — |
| Q2 2025 | 2025-06-30 | −$220.9M | $272.2M | — |
| Q1 2025 | 2025-03-31 | −$259.7M | $324.4M | — |
| Q4 2024 | 2024-12-31 | −$316.8M | $51.5M | — |
| Q3 2024 | 2024-09-30 | −$1.02B | −$490.9M | — |
| Q2 2024 | 2024-06-30 | −$493.1M | $22.7M | — |
| Q1 2024 | 2024-03-31 | −$584.1M | −$220.2M | — |
| Q4 2023 | 2023-12-31 | −$368.2M | $448.5M | — |
| Q3 2023 | 2023-09-30 | −$531.3M | −$272.7M | — |
| Q2 2023 | 2023-06-30 | −$515.8M | −$298.9M | — |
| Q1 2023 | 2023-03-31 | −$363.9M | −$184.5M | — |
| Q4 2022 | 2022-12-31 | −$816.7M | −$764.5M | — |
| Q3 2022 | 2022-09-30 | −$258.6M | −$147.7M | — |
| Q2 2022 | 2022-06-30 | −$217.0M | −$66.9M | — |
| Q1 2022 | 2022-03-31 | −$179.3M | $18.5M | — |
| Q4 2021 | 2021-12-31 | −$52.2M | $334.0M | — |
| Q3 2021 | 2021-09-30 | −$110.9M | — | — |
| Q2 2021 | 2021-06-30 | −$150.1M | — | — |
| Q1 2021 | 2021-03-31 | −$197.8M | — | — |
| Q4 2020 | 2020-12-31 | −$386.2M | −$327.4M | — |
| Q4 2019 | 2019-12-31 | −$58.8M | — | — |
Vaxcyte net debt trends
Over the last five fiscal years, Vaxcyte's net debt increased from −$386.2M to −$56.4M, a change of $329.8M. The latest reported quarter, Q2 2026, shows −$67.7M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vaxcyte source filings ↗